This is of clinical relevance, since activating BRAF mutations are frequently observed in MM but the therapeutic benefit of selective BRAF inhibitors like vemurafenib may be limited due to bypassing mechanisms like secondary NRAS mutations [38]. This evidence concerns the gene NRAS and Miyoshi myopathy.